Research programme: PDGFR tyrosine kinase inhibitors - Johnson & Johnson
Alternative Names: JNJ-10198409; Research programme: platelet-derived growth factor receptor tyrosine kinase inhibitors - Johnson & Johnson; RWJ-540973Latest Information Update: 16 Jul 2016
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Class Pyrazoles
- Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 21 Apr 2004 Preclinical trials in Cancer in USA (PO)